Genprex advances GPX-002 diabetes gene therapy program

Genprex ( (GNPX) ) has shared an update.

On January 7, 2026, Genprex reported 2025 progress and near-term plans for its GPX-002 diabetes gene therapy program, highlighting expansion of preclinical research into Type 2 diabetes animal models, where in vivo studies showed proof-of-concept by rejuvenating exhausted beta cells and normalizing glucose levels. The company also moved manufacturing of GPX-002 from academic partners to its network of contract development and manufacturing organizations and requested a meeting with the U.S. Food and Drug Administration, scheduled for the first quarter of 2026, to define IND-enabling preclinical studies, while preparing for clinical-scale cGMP manufacturing, product optimization including a non-viral lipid nanoparticle delivery approach, and toxicology studies that are expected to support a future IND filing and potential initiation of human trials, signaling a pivotal operational step in positioning Genprex within the emerging diabetes gene therapy field.

More about Genprex

Genprex, Inc. is a clinical-stage biotechnology company developing gene therapies, including GPX-002, a diabetes gene therapy candidate targeting both Type 1 and Type 2 diabetes. The company focuses on transforming pancreatic cells to restore insulin production and normalize glucose levels, supported by an integrated network of contract development and manufacturing organizations and academic collaborators as it advances its pipeline toward human clinical trials.

Average Trading Volume: 785,606

Technical Sentiment Signal: Sell

Current Market Cap: $4.17M

See more insights into GNPX stock on TipRanks’ Stock Analysis page.